Regulation of HHLA2 expression in kidney cancer and myeloid cells

BACKGROUND: The immune checkpoint HERV-H LTR-associating 2 (HHLA2) is expressed in kidney cancer and various other tumor types. Therapeutics targeting HHLA2 or its inhibitory receptor KIR3DL3 are being developed for solid tumors, including renal cell carcinoma (RCC). However, the regulation of HHLA2...

Descripción completa

Detalles Bibliográficos
Autores principales: Shigemura, Tomonari, Perrot, Nahuel, Huang, Zimo, Bhatt, Rupal S., Sheshdeh, Aseman Bagheri, Ahmar, Nourhan El, Ghandour, Fatme, Signoretti, Sabina, McDermott, David F., Freeman, Gordon J., Mahoney, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605970/
https://www.ncbi.nlm.nih.gov/pubmed/37891555
http://dx.doi.org/10.1186/s12885-023-11496-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605970/
https://www.ncbi.nlm.nih.gov/pubmed/37891555
http://dx.doi.org/10.1186/s12885-023-11496-9

Ejemplares similares